ATLANTA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO) complied with federal securities laws. On December 29, 2025, Mereo announced the results from its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, revealing that, “[n]either study achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bis ...